Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10072-020-04273-0 | DOI Listing |
J Nucl Med
December 2023
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California;
Tau PET has enabled the visualization of paired helical filaments of 3 or 4 C-terminal repeat tau in Alzheimer disease (AD), but its ability to detect aggregated tau in frontotemporal lobar degeneration (FTLD) spectrum disorders is uncertain. We investigated 2-(2-([F]fluoro)pyridin-4-yl)-9-pyrrolo[2,3-b:4,5c']dipyridine ([F]PI-2620), a newer tracer with ex vivo evidence for binding to FTLD tau, in a convenience sample of patients with suspected FTLD and AD using a static acquisition protocol and parametric SUV ratio (SUVr) images. We analyzed [F]PI-2620 PET data from 65 patients with clinical diagnoses associated with AD or FTLD neuropathology; most (60/65) also had amyloid-β (Aβ) PET.
View Article and Find Full Text PDFFront Aging Neurosci
August 2022
Division of General Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
: Two common variants of sortilin-related receptor 1 gene (), rs2298813 and rs1784933, have been associated with late-onset Alzheimer's disease (AD) in the Han Chinese population in Taiwan. However, neuroimaging correlates of these two variants remain unknown. We aimed to determine whether the two polymorphisms were associated with any volumetric differences in brain regions in late-onset AD patients.
View Article and Find Full Text PDFDiagnostics (Basel)
June 2022
Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
Hyperintensities within the bilateral globus pallidus on T1-weighted magnetic resonance images were present in some liver cirrhosis patients with hepatic encephalopathy. The symptoms of covert hepatic encephalopathy are similar to those of mild dementia. We aimed to develop a new diagnostic index in which to distinguish hepatic encephalopathy from dementia.
View Article and Find Full Text PDFExpert Rev Neurother
September 2022
Department of Neurosurgery, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, Germany.
Introduction: Huntington's Disease as progressive neurological disorders associated with motor, behavioral, and cognitive impairment poses a therapeutic challenge in case of limited responsiveness to established therapeutics. Pallidal deep brain stimulation and neurorestorative strategies (brain grafts) scoping to modulate fronto-striatal circuits have gained increased recognition for the treatment of refractory Huntington's disease (HD).
Areas Covered: A review (2000-2022) was performed in PubMed, Embase, and Cochrane Library covering clinical trials conceptualized to determine the efficacy and safety of invasive, stereotactic-guided deep-brain stimulation and intracranial brain-graft injection targeting the globus pallidus and adjunct structures (striatum).
Front Aging Neurosci
March 2021
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Tau-specific positron emission topography (PET) imaging enables assessment of Alzheimer's disease (AD). We aimed to investigate its performance in combination with plasma tau levels in patients with non-AD tauopathy. A total of 47 participants were enrolled, including 10 healthy controls, 16 with tauopathy parkinsonism syndromes (9 with corticobasal syndrome [CBS], 7 with progressive supranuclear palsy [PSP]), 9 with frontotemporal dementia (FTD), 4 with AD, and 8 with Parkinson's disease (PD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!